Guardant Health up as cancer detection test gets FDA's 'breakthrough' tag

Shares of medical diagnostics firm Guardant Health GH.O up 7.5% at $45.25

GH says the U.S. FDA has granted "breakthrough" tag for its device to detect multiple types of cancer

The multi-cancer detection (MCD) test uses a blood sample to screen for different cancer types in patients aged 45 or older

FDA's breakthrough devices program is intended to provide patients and health care providers with timely access to medical devices by speeding up development, assessment, and review, according to its website

Including session's move, stock up 46.8% YTD